CN105942510A - Medical energy nutrition component applied to pregnant and lying-in women and preparation method thereof - Google Patents
Medical energy nutrition component applied to pregnant and lying-in women and preparation method thereof Download PDFInfo
- Publication number
- CN105942510A CN105942510A CN201610350096.3A CN201610350096A CN105942510A CN 105942510 A CN105942510 A CN 105942510A CN 201610350096 A CN201610350096 A CN 201610350096A CN 105942510 A CN105942510 A CN 105942510A
- Authority
- CN
- China
- Prior art keywords
- group
- oil
- pregnant
- preparation
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims description 25
- 235000016709 nutrition Nutrition 0.000 title abstract description 22
- 230000035764 nutrition Effects 0.000 title abstract description 11
- 235000013343 vitamin Nutrition 0.000 claims abstract description 32
- 239000011782 vitamin Substances 0.000 claims abstract description 32
- 229940088594 vitamin Drugs 0.000 claims abstract description 32
- 229930003231 vitamin Natural products 0.000 claims abstract description 32
- 235000015097 nutrients Nutrition 0.000 claims abstract description 15
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 15
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 15
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 13
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 38
- 230000035935 pregnancy Effects 0.000 claims description 24
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 23
- 235000010755 mineral Nutrition 0.000 claims description 23
- 239000011707 mineral Substances 0.000 claims description 23
- 239000000843 powder Substances 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 239000003921 oil Substances 0.000 claims description 14
- 235000019198 oils Nutrition 0.000 claims description 14
- 239000012071 phase Substances 0.000 claims description 14
- 235000018102 proteins Nutrition 0.000 claims description 14
- 239000000839 emulsion Substances 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 8
- 235000019197 fats Nutrition 0.000 claims description 7
- 210000000582 semen Anatomy 0.000 claims description 7
- 239000008346 aqueous phase Substances 0.000 claims description 6
- 239000011573 trace mineral Substances 0.000 claims description 6
- 235000013619 trace mineral Nutrition 0.000 claims description 6
- 235000003935 Hippophae Nutrition 0.000 claims description 5
- 241000229143 Hippophae Species 0.000 claims description 5
- 235000019486 Sunflower oil Nutrition 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 5
- 239000002600 sunflower oil Substances 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 229920000881 Modified starch Polymers 0.000 claims description 4
- 241001597008 Nomeidae Species 0.000 claims description 4
- 235000019485 Safflower oil Nutrition 0.000 claims description 4
- 235000021120 animal protein Nutrition 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 235000014633 carbohydrates Nutrition 0.000 claims description 4
- 210000003022 colostrum Anatomy 0.000 claims description 4
- 235000021277 colostrum Nutrition 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 229920001592 potato starch Polymers 0.000 claims description 4
- 235000005713 safflower oil Nutrition 0.000 claims description 4
- 239000003813 safflower oil Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- 229920002774 Maltodextrin Polymers 0.000 claims description 3
- 239000005913 Maltodextrin Substances 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 108010073771 Soybean Proteins Proteins 0.000 claims description 3
- 239000005018 casein Substances 0.000 claims description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 3
- 235000021240 caseins Nutrition 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 230000001804 emulsifying effect Effects 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 229940035034 maltodextrin Drugs 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 235000019710 soybean protein Nutrition 0.000 claims description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- PVXPPJIGRGXGCY-TZLCEDOOSA-N 6-O-alpha-D-glucopyranosyl-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-TZLCEDOOSA-N 0.000 claims description 2
- 240000002900 Arthrospira platensis Species 0.000 claims description 2
- 235000016425 Arthrospira platensis Nutrition 0.000 claims description 2
- 102000011632 Caseins Human genes 0.000 claims description 2
- 108010076119 Caseins Proteins 0.000 claims description 2
- 241000195649 Chlorella <Chlorellales> Species 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 229920002261 Corn starch Polymers 0.000 claims description 2
- 102000002322 Egg Proteins Human genes 0.000 claims description 2
- 108010000912 Egg Proteins Proteins 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 101000693916 Gallus gallus Albumin Proteins 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 244000017020 Ipomoea batatas Species 0.000 claims description 2
- 235000002678 Ipomoea batatas Nutrition 0.000 claims description 2
- 102000004407 Lactalbumin Human genes 0.000 claims description 2
- 108090000942 Lactalbumin Proteins 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- 240000003183 Manihot esculenta Species 0.000 claims description 2
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 claims description 2
- 239000004368 Modified starch Substances 0.000 claims description 2
- 241000195663 Scenedesmus Species 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 235000021307 Triticum Nutrition 0.000 claims description 2
- 244000098338 Triticum aestivum Species 0.000 claims description 2
- 235000019498 Walnut oil Nutrition 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- 239000000828 canola oil Substances 0.000 claims description 2
- 235000019519 canola oil Nutrition 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008120 corn starch Substances 0.000 claims description 2
- -1 correctives Substances 0.000 claims description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 235000021323 fish oil Nutrition 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000004816 latex Substances 0.000 claims description 2
- 229920000126 latex Polymers 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 235000019426 modified starch Nutrition 0.000 claims description 2
- 239000004006 olive oil Substances 0.000 claims description 2
- 235000008390 olive oil Nutrition 0.000 claims description 2
- 238000012856 packing Methods 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 2
- 239000003549 soybean oil Substances 0.000 claims description 2
- 235000012424 soybean oil Nutrition 0.000 claims description 2
- 239000008347 soybean phospholipid Substances 0.000 claims description 2
- 229940082787 spirulina Drugs 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000008170 walnut oil Substances 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims 1
- 210000004681 ovum Anatomy 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- XXRYFVCIMARHRS-UHFFFAOYSA-N propan-2-yl n-dimethoxyphosphorylcarbamate Chemical compound COP(=O)(OC)NC(=O)OC(C)C XXRYFVCIMARHRS-UHFFFAOYSA-N 0.000 claims 1
- 239000013049 sediment Substances 0.000 claims 1
- 239000000741 silica gel Substances 0.000 claims 1
- 229910002027 silica gel Inorganic materials 0.000 claims 1
- 150000005846 sugar alcohols Chemical class 0.000 claims 1
- 239000002023 wood Substances 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 15
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract description 5
- 235000019152 folic acid Nutrition 0.000 abstract description 3
- 239000011724 folic acid Substances 0.000 abstract description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 abstract description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 abstract description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 abstract description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 abstract description 2
- 229960000304 folic acid Drugs 0.000 abstract description 2
- 235000019155 vitamin A Nutrition 0.000 abstract description 2
- 239000011719 vitamin A Substances 0.000 abstract description 2
- 229940045997 vitamin a Drugs 0.000 abstract description 2
- 229930003451 Vitamin B1 Natural products 0.000 abstract 1
- 229960003495 thiamine Drugs 0.000 abstract 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 abstract 1
- 235000010374 vitamin B1 Nutrition 0.000 abstract 1
- 239000011691 vitamin B1 Substances 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 51
- 230000000994 depressogenic effect Effects 0.000 description 22
- 230000037396 body weight Effects 0.000 description 17
- 241000700159 Rattus Species 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 230000000576 supplementary effect Effects 0.000 description 15
- 210000004556 brain Anatomy 0.000 description 12
- 239000000047 product Substances 0.000 description 10
- 235000015872 dietary supplement Nutrition 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 230000006399 behavior Effects 0.000 description 8
- 230000009182 swimming Effects 0.000 description 8
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000035606 childbirth Effects 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 230000000050 nutritive effect Effects 0.000 description 6
- 238000010254 subcutaneous injection Methods 0.000 description 6
- 239000007929 subcutaneous injection Substances 0.000 description 6
- 201000009916 Postpartum depression Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 208000007502 anemia Diseases 0.000 description 4
- 210000003754 fetus Anatomy 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000012048 forced swim test Methods 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010013911 Dysgeusia Diseases 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 206010021703 Indifference Diseases 0.000 description 2
- 206010027336 Menstruation delayed Diseases 0.000 description 2
- 208000009233 Morning Sickness Diseases 0.000 description 2
- 208000034850 Vomiting in pregnancy Diseases 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 235000019890 Amylum Nutrition 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- 101100381997 Danio rerio tbc1d32 gene Proteins 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 244000182067 Fraxinus ornus Species 0.000 description 1
- 235000002917 Fraxinus ornus Nutrition 0.000 description 1
- 208000035223 Gestational Weight Gain Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010021000 Hypoglycaemic coma Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 101100381999 Mus musculus Tbc1d32 gene Proteins 0.000 description 1
- 208000001300 Perinatal Death Diseases 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- FRYDSOYOHWGSMD-UHFFFAOYSA-N [C].O Chemical compound [C].O FRYDSOYOHWGSMD-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000027326 copulation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 1
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 230000021824 exploration behavior Effects 0.000 description 1
- 230000004578 fetal growth Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 230000003534 oscillatory effect Effects 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 208000026440 premature labor Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 235000020795 whole food diet Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention relates to the field of total nutrient food with special medical purposes, in particular to a series of nutrients for pregnant and lying-in women and breast-feeding women at different stages, and provides a medical energy nutrition component applied to pregnant and lying-in women. The medical energy nutrition component comprises vitamin and energy components and energy components, the vitamin and energy components contain folic acid, vitamin A, vitamin B1 and the like, and the energy components contain protein, fat and carbohydrate.
Description
Technical field
The present invention relates to the wholefood field with special medicine purposes, in particular for the pregnant and lying-in women of different times
And women breast-feeding their children provide a series of nutrient.
Background technology
Trimester of pregnancy is special physiological period in women life.Trimester of pregnancy women is due to blood volume and erythrocyte number
Increase, circulate mesotrophic associated proteins and micronutrient level decrease, add the metabolism of anemia of pregnant woman also
The demand of fetal growth to be met, the demand of various nutrition, as a Ge Gao nutritional need colony, all be increased by anemia of pregnant woman, because of
This easily causes the shortage of various vitamin and mineral.Existing clinical evidence the most tentatively shows, some vitamin and ore deposit
Material plays very important effect at the healthy aspect safeguarding pregnancy women, lacks these vitamin and mineral may be led
Cause the increase of anemia of pregnant woman's various gestation ill danger of syndrome, cause miscarriage, stillbirth, monster, neonatal death, premature labor and puerperal
, between maternal nutritional and the brain development of fetus and intelligent development, all there is close relationship in massive hemorrhage etc. simultaneously.But trimester of pregnancy
Different phase each nutritional labeling demand is not quite similar, such as general First Trimester (≤12 weeks) shortage folic acid and vitamin
A is more serious, and mid trimester of pregnancy (13～27 weeks), late trimester of pregnancy (>=28 weeks) and age of sucking calcium deficiency the most serious.Another 22
Carbon acid (DHA) is a kind of polyunsaturated fatty acid very important to human body, is that brain becomes with amphiblestroid important composition
Point, therefore most important to tire infant intelligence and visual acuity.The most quick growth and development stage of brain be period of fetus and 0～
1 year old is during this period of time, and in infant brain, 60% is fat, and wherein 20% is Omega-3 fatty acid, and it mainly includes DHA, thus pregnant
The women being pregnent phase and age of sucking supplements DHA and just seems particularly necessary.
Protein is the important nutritional labeling forming brains, hair, internal organs, fingernail, blood, muscle etc., and serves increasing
Strong uteroplacental effect, if the intake of protein is not enough, not only hinders the normal development of fetus, also can cause parent
Metabolism disorder.Fat is indispensable nutrient substance in early pregnant women body, and it promotes the suction of fatsoluble vitamin E
Receiving, play antiabortive effect, fat can help the position of fixing internal organs, makes uterus homeostasis central at pelvic cavity, to embryo
Grow and a peaceful environment is provided.Additionally, the most protected skin of fat, teleneuron, blood vessel and the effect of internal organs.Carbon aquation
Compound is the main source of heat, lacks carbohydrate and will cause general weakness, tired, blood sugar content fall in diet for pregnant woman
Low, produce the symptoms such as dizziness, cardiopalmus, disordered brain function and occur, severe patient can cause trimester of pregnancy hypoglycemic coma, to anemia of pregnant woman's health
Cause pressure, be all disadvantageous to self and baby's health.
Along with China's expanding economy and the raising of living standards of the people, occur in that substantial amounts of for motherhood in the market
The nutritional health food of woman, but these are all fixing formulation products, and energy supplements together with vitamin, mineral, does not also have pin
To the specific products of Different Nutrition composition needed for different trimester of pregnancy and women breast-feeding their children, and in the market for pregnant and lying-in women and the food in one's mouth
The nutraceutical of breast phase women is all without DHA, and some is possibly together with some hormones, therefore can not meet clinical treatment and health care demand.
Summary of the invention
It is an object of the invention to for different trimester of pregnancy and the difference of women breast-feeding their children's desired nutritional composition, it is provided that personalized
The special medical nutraceutical of formula, including vitamins and minerals assembly and power pack, vitamins and minerals assembly is also simultaneously
Containing DHA, balanced in nutrition.Two kinds of assemblies can alone also can be combined, and pregnant and lying-in women can be according to self residing stages of gestation and battalion
Support absorption situation and select vitamins and minerals assembly and power pack flexibly, provide nutrition and energy supplement for pregnant and lying-in women, thus
Effectively ensure trimester of pregnancy and the health of women breast-feeding their children and fetus physique, intelligent development.
For achieving the above object, the present invention is by the following technical solutions:
A kind of energy nutrient compositions for pregnant and lying-in women, described compositions is selected from vitamins and minerals assembly and energy bins
Part, wherein said vitamins and minerals assembly contains following component
Wherein said power pack contains following component: protein, fat, carbohydrate, three accounts for energy bins respectively
The 12%～20%, 20%～30% of part weight, 55%～65%.
The present invention further investigation revealed that, different phase puerpera's desired nutritional of gestation is different, develops difference for this
Formula, for First Trimester: described vitamins and minerals assembly contains following component:
For mid trimester of pregnancy, described vitamins and minerals assembly contains following component:
For late trimester of pregnancy, described vitamins and minerals assembly contains following component:
For age of sucking, described vitamins and minerals assembly contains following component:
Compositions of the present invention, the protein in wherein said power pack is selected from animal protein and vegetable protein
Matter, wherein animal protein is selected from: one or more in casein, lactalbumin, collagen protein, Chicken Albumin；Plant egg
White matter is selected from: soybean protein, Semen Pisi sativi protein, Semen phaseoli radiati albumen, Semen sojae atricolor albumen, wheat protein, zein, Semen oryzae sativae albumen, Herba bromi japonici
Albumen, seed of Fructus Hippophae albumen, spirulina protein, chlorella albumen, scenedesmus albumen one or more,
Fat in wherein said power pack is selected from: Petiolus Trachycarpi oil, Oleum Cocois, Oleum Brassicae campestris (including Canola oil),
Semen Lini oil, sunflower oil (including high oleic sunflower oil), soybean oil, safflower oil (including high oleic safflower oil), Radix Oenotherae erythrosepalae oil, sand
One or more in spine seed oil, Oleum Hippophae, olive oil, walnut oil, fish oil, the carbon hydrate in wherein said power pack
Thing is selected from: fructose, glucose, sucrose, maltose, isomaltulose, xylitol, maltodextrin, tapioca, corn starch,
One or more in potato starch, sweet potato starch, modified starch.
Compositions of the present invention, is preferably prepared to the dosage form being suitable for taking, and described preparation is selected from: dissipate
Agent, granule, capsule, tablet, Emulsion.
Compositions of the present invention, described dosage form, wherein comprise the carrier that can take, described carrier is selected from filling out
Filling agent, binding agent, lubricant, correctives, surfactant, wherein filler is selected from amylum pregelatinisatum, pregelatinized Starch, manna
One or more in alcohol, microcrystalline Cellulose, lactose, binding agent is selected from polyvidone, hydroxypropyl methylcellulose, hydroxymethyl cellulose
Sodium, hydroxypropyl cellulose, ethyl cellulose one or more, lubricant be selected from magnesium stearate, sodium stearyl fumarate, micropowder silicon
Glue and talcous one or more, surfactant selected from soybean phospholipid and derivant, lecithin and derivant thereof, tell
One or more in temperature, span.Present invention additionally comprises the preparation method of compositions of the present invention, including by each in prescription
The step of composition mixing.
Preparation method of the present invention, wherein vitamins and minerals assembly and power pack can be prepared as respectively
Agent, can separately take, it is also possible to take simultaneously, and wherein vitamins and minerals assembly is preferably prepared to solid preparation, specifically makes
Standby process comprises the following steps:
1), after vitamin, trace element mixing, 100 mesh sieves are crossed；
2), the solid containing DHA is crossed 100 mesh sieves；
3), by packing after above two powder mix homogeneously, powder is i.e. obtained；
4) or by after above two powder mix homogeneously, add appropriate amount of auxiliary materials and make granule, make corresponding system the most again
Agent；
Wherein power pack is preferably prepared to Emulsion, and the concrete preparation process of Emulsion comprises the following steps:
1) oil phase and aqueous phase, are prepared；
2), oil phase and aqueous phase are mixed, use high speed emulsion dispersion machine to carry out emulsifying, prepare colostrum；
3), regulate to target ph with sodium hydroxide solution, add water and be settled to full dose；
4) use high pressure homogenizer homogenizing, again, obtain homogeneous latex emulsion；
5), fill, sterilizing, to obtain final product.
The invention has the beneficial effects as follows:
The present invention is that pregnant and lying-in women provide a kind of tool high nutritive value product, and on this basis, the present invention further grinds
Studying carefully discovery, different phase puerpera's desired nutritional of gestation is different, develops different formula for this, balanced in nutrition, is particularly suitable for
In pregnant and lying-in women and women breast-feeding their children.
The present invention is according to pregnant phase morning, noon and afternoon and age of sucking different nutritional need, and it is more careful to carry out each constituent content
Adjustment, for different times pregnant and lying-in women provide personalized solution.Main advantage is as follows:
The most pregnant early production folate content is more reasonable with like product on the market.
The most pregnant early production forced for vitamins B6 and manganese, can alleviate morning sickness.
3. vitamin d3 levels more meets the Endocrine Society of the Chinese Medical Association recommended amounts to pregnant and lying-in women, more meets present situation.
The content of the most pregnant product raising in late period calcium constituent, to meet substantial amounts of calcium demand in pregnant late period.
5. ferrum element adds more personalized, and pregnant early production because of pregnant early stage physical feature, lacks situation rare, in addition by
Sensitive to rust taste in morning sickness, therefore pregnant early production is not added with ferrum element, and pregnant middle and advanced stage product iron-holder meets guide
Recommend, more reasonable with like product on market, do not easily cause the risk of iron doping.
The present invention is advantageous in that another, it is a discovery of the invention that take the preparation of the present invention according to the method for the present invention, produces
Depression is decreased obviously.
Pregnant mouse motherhood nutriture is improved the mistake tested by the medical energy nutrient preparation of motherhood carried out in early stage
Cheng Zhong, it was observed that the symptoms such as the most movable minimizing, passive activity increase, love cub minimizing occurs in the dams of blank group,
According to correlational study, this symptom may be closely related with postpartum depression.And it has been surprisingly found that supplementary group occurs
The dams of this clinical symptoms is less, it can be seen that, supplementary is likely to be of the effect of anti-postpartum depression.Therefore, carry out
Supplementary alleviates the relevant animal research of postpartum depression effect, and experimental study situation is as follows:
Test objective:
With supplementary as tested material, Pregnant rats oral administration, observe parent, embryo and the battalion of ablactation children Mus
Support effect；Observe supplementary to pregnant Mus postpartum depression mitigation simultaneously.
Test method:
Laboratory animal
Beijing company of dimension tonneau China provides Wistar female of child bearing age rat 180 (body weight 180 ± 10g), and bull is big
Mus 90 (body weight 220 ± 15g).
Experiment feedstuff
Normal feedstuff formula see table 1
Table 1 normal feedstuff table
Experimental drug:
Normal saline
Injection dexamethasone sodium phosphate
Supplementary (energy nutrient compositions of the present invention mixes with equivalent water)
Ordinary nutritional supplement (on market buy containing vitamin, mineral, (Chinese Chen Shi is pregnant for the nutritive powder of protein
Woman's high-protein nutrient powder) mix with equivalent water)
Method and testing index
The foundation of pregnant mouse model
By body weight, whole female Mus and male Mus are randomly divided into A/B/C/D/E/F 6 groups respectively, and female Mus often organizes 30, and male Mus is every
Organize 15, first feed with normal feedstuff and observe 1 week, then male and female rat is carried out same cage copulation by the ratio of 2:1, take morning next day
Female Mus vaginal orifice secretions carries out microscopy, finds that sperm is Pregnant rats, is raised by Pregnant rats list cage, it is ensured that often organize pregnant Mus
20.
Packet:
Depressed group:
A group: give normal feedstuff, become pregnant subcutaneous injection 0.2ml kg every day-1·d-1Dexamethasone sodium phosphate is to dividing
Childbirth, is administered orally 6ml normal saline every day.
B group: give normal feedstuff, become pregnant subcutaneous injection 0.2ml kg every day-1·d-1Dexamethasone sodium phosphate is to dividing
Childbirth, is administered orally 6ml supplementary every day.
C group: give normal feedstuff, become pregnant subcutaneous injection 0.2ml kg every day-1·d-1Dexamethasone sodium phosphate is to dividing
Childbirth, is administered orally 6ml ordinary nutritional supplement every day.
Non-depressed group:
D group: give normal feedstuff, become pregnant subcutaneous injection 0.2ml kg every day-1·d-1Normal saline is to childbirth, every day
Oral 6ml normal saline.
E group: give normal feedstuff, become pregnant subcutaneous injection 0.2ml kg every day-1·d-1Normal saline is to childbirth, every day
Oral 6ml supplementary.
F group: give normal feedstuff, become pregnant subcutaneous injection 0.2ml kg every day-1·d-1Normal saline is to childbirth, every day
Oral 6ml ordinary nutritional supplement.
Each group Pregnant rats is freely ingested and drinks water.Pregnant Mus body weight and the forage volume ingested is claimed every 3 days.
Evaluation of nutrition
Rat Pregnancy phase testing index
The pregnancy period of rat is 21 days.Before pregnant, pregnant in each group of (the 12nd day) and pregnant latter stage (the 20th day, the most first 1 day)
Measure hemoglobin level (cyaniding), trimester of pregnancy weightening finish and food titer (efficiency of feed utilization).Treat that each group of pregnant Mus is the most pregnant
During to the 20th day, by pregnant for numbering odd number Mus take out, with cervical dislocation put to death, check live tire number, measure tire Mus body weight, height and
The Growth and development indexes such as tail length.With the group pregnant Mus of even number to spontaneous labor.
Rat testing index age of sucking
Rat age of sucking is 23 days.Measure during this period: birth children's Mus number, (the filial mice survival in 4 days puerperal of birth survival rate
Live during number/birth young number × 100), nurture survival rate (during ablactation in 21 days after filial mice survival number/birth 4 days filial mice survive number ×
100) and ablactation children's Mus height, body weight, endurance (swimming with a load attached to the body to sinking to the bottom, calculate time), and intelligent test (step on water maze
Bank is tested).After all experiments completes, kill children Mus and take brain and weigh, calculate brain body ratio.
Above experimental data withRepresenting, between two samples, the significant difference of mean makees t inspection.
Result
The pregnant Mus body weight of each group and food titration result (table 2) during experiment, table 2 shows, the food titer of the pregnant Mus of A group
(food utilization) is significantly lower than B group and C group (P < 0.01)；B group pregnant Mus food titer is apparently higher than C group (P < 0.05)；D group is pregnant
Mus food titer (food utilization) is significantly lower than E group and F group (P < 0.05)；E group pregnant Mus food titer apparently higher than F group (P <
0.05)；C group, compared with E group, there was no significant difference (P > 0.05).
Brief summary
From result, the pregnant Mus of A group is compared with B group and C group, and food titer significantly reduces, and this shows, supplementary with
Ordinary nutritional supplement are respectively provided with nutritional supplementation effect, and B group pregnant Mus food utilization is apparently higher than C group, and this shows that my company opens
The nutritional supplementation effect of the supplementary sent out is better than ordinary nutritional supplement.C group compared with E group, there was no significant difference (P >
0.05), but C group food valence value is less than E group, illustrates that pregnant Mus depression may have impact on its food intake, and supplementary can
Can alleviate depression effect, therefore compared with non-depressed pregnant Mus, its food potency differences is inconspicuous.
The pregnant Mus body weight of each group and food titration result during table 2 experiment
* with B group compares P < 0.01* with B group and compares P < 0.05
P < 0.01 is compared with C groupP < 0.05 is compared with C group
++P < 0.01 is compared with E group；+ compare P < 0.05 with E group
§§P < 0.01 is compared with F group；§ with F group compares P < 0.05
Rat before pregnant, pregnant in and pregnant hemoglobinometry in latter stage result (table 3)
Table 3 is visible, pregnant latter stage A group rat hemoglobin level not only significantly lower than B group and C group (P < 0.01), also
Relatively from low in pregravidic content；B group is apparently higher than C group (P < 0.05)；D group hemoglobin level is significantly lower than E group and F group
(P < 0.01), low compared with content before self gestation；E is apparently higher than F group (P < 0.05).
Brief summary
Be there is the work improving hemoglobin level by result of the test, supplementary and ordinary nutritional supplement
With, and the supplementary effect of my company exploitation is better than ordinary nutritional supplement.By depressed group (A/B/C group) and non-depressed
(D/E/F group) group compares, although each matched group (A/D group；B/E group；C/F group) there was no significant difference, but depressed group data are equal
Less than non-depressed group, this is likely due to ingesting of the pregnant Mus of Geriatric Depression and causes nutritive index data slightly difference.
Table 3 respectively organize rat before pregnant, pregnant in and pregnant hemoglobinometry in latter stage result
| Group | Number of animals | Before pregnant | Second trimester | Pregnant latter stage |
| A | 20 | 125.5±8.7 | 108.5±23.1 | 113.7±10.5** |
| B | 20 | 125.9±9.2 | 115.3±21.8 | 125.5±11.4 |
| C | 20 | 124.8±8.1 | 117.3±24.3 | 122.2±10.9 |
| D | 20 | 124.8±8.1 | 109.3±24.3 | 115.5±10.9§§++ |
| E | 20 | 125.3±10.8 | 114.1±20.6 | 125.6±12.4+ |
| F | 20 | 123.7±9.1 | 112.8±25.1 | 122.5±12.3 |
* with B group compares P < 0.01* with B group and compares P < 0.05
P < 0.01 is compared with C groupP < 0.05 is compared with C group
++P < 0.01 is compared with E group；+ compare P < 0.05 with E group
§§P < 0.01 is compared with F group；§ with F group compares P < 0.05
Each group rat pregnant tire Mus number of institute and development index (table 4) thereof
Shown in table 4, the tire Mus tire the most alive that the pregnant Mus of each group is pregnant, have no deformity on inspection.Litter size amount is all without notable
Difference (P > 0.05).Tire son's body weight, height, tail length compare, and in depressed group, A group is significantly less than B group and C group (P < 0.01), and B group is bright
Aobvious more than C group (P < 0.05).In non-depressed group, D group is significantly less than E group and F group (P < 0.01), E group significantly greater than F group (P <
0.05).Depression is organized and respective matched group (A/D group in non-depressed group；B/E group；C/F group) there was no significant difference, but depressed group
Data are below non-depressed group, and this is likely due to the index of correlation of the pregnant Mus of Geriatric Depression.
Table 4 respectively organizes tire Mus number, body weight, height and the long measurement result of tail
| Group | Pregnant Mus number | Tire Mus number | Body weight (g) | Height (cm) | Tail length (cm) |
| A | 10 | 10.95±3.10 | 3.56±0.20** | 3.81±0.03** | 1.11±0.03** |
| B | 10 | 11.25±2.95 | 4.54±0.20 | 4.03±0.04 | 1.37±0.02 |
| C | 10 | 11.19±1.59 | 4.01±0.29 | 3.99±0.10 | 1.27±0.04 |
| D | 10 | 10.98±2.99 | 3.57±0.19§§++ | 3.85±0.01§§++ | 1.14±0.04§§++ |
| E | 10 | 11.36±2.98 | 4.55±0.19+ | 4.19±0.08+ | 1.39±0.05+ |
| F | 10 | 11.34±3.11 | 4.04±0.37 | 4.04±0.04 | 1.28±0.02 |
* with B group compares P < 0.01* with B group and compares P < 0.05
P < 0.01 is compared with C groupP < 0.05 is compared with C group
++P < 0.01 is compared with E group；+ compare P < 0.05 with E group
§§P < 0.01 is compared with F group；§ with F group compares P < 0.05
Each group pregnant Mus produced young baby number, birth survival rate and nurture survival rate
Each group pregnant Mus produced young baby number: A group 63, B group 66, C group 68, D group 62, E group 69, F group 68.Produce
All survivals in latter 4 days, respectively organize children Mus and also survive during ablactation.Each group birth survival rate and the nurture equal indifference of survival rate.
Respectively organize ablactation children's Mus development index and maze test and endurance test result (table 5)
Table 5 shows, A group ablactation paedomorphosis index in depressed group: body weight, height and swimming time (endurance) are surveyed
Test result, each statistical average is below B group and C group (P < 0.01), and the water maze time of going ashore be longer than B group and C group (P <
0.01) the other nonsignificance of the brain method of double differences (P > 0.05), and is respectively organized.B group ablactation paedomorphosis index: body weight, height and
Swimming time (endurance) test result, each statistical average all be higher than C group, and water maze go ashore the time less than C group (P <
0.01) the other nonsignificance of the brain method of double differences (P > 0.05), and is respectively organized.
E group ablactation paedomorphosis index in non-depressed group: body weight, height and swimming time (endurance) test knot
Really, each statistical average is below E group and F group (P < 0.01), and the water maze time of going ashore is longer than E group and F group (P < 0.01),
And respectively organize the other nonsignificance of the brain method of double differences (P > 0.05).E group ablactation paedomorphosis index: when body weight, height and swimming
Between (endurance) test result, each statistical average is all higher than F group, and water maze time of going ashore is less than F group (P < 0.01), and
The each group other nonsignificance of the brain method of double differences (P > 0.05).Depression is organized and respective matched group (A/D group in non-depressed group；B/E group；C/F
Group) there was no significant difference, but depressed group data are below non-depressed group, and this is likely due to the phase of the pregnant Mus of Geriatric Depression
Close index.
Table 5 respectively organizes ablactation children's Mus body weight, brain weight, height, water maze and swimming time measurement result
| Group | Body weight (g) | Brain weight (g) | Height (cm) | Water maze test (s) | Swimming time (s) |
| A | 32.3±4.9(63)** | 1.02±0.05(61) | 9.2±0.43(63)** | 21.3±7.59(63)** | 22±11.9(63)** |
| B | 38.5±5.2(66) | 1.09±0.08(66) | 11.5±0.72(66) | 13.6±7.81(66) | 113±75(66) |
| C | 35.3±5.1(68) | 1.07±0.05(68) | 10.9±0.28(68) | 17.3±5.2(68) | 108±79(68) |
| D | 32.4±4.8(62)§§++ | 1.01±0.07(60)§§++ | 10.1±0.45(62)§§++ | 21.5±7.61(62)§§++ | 23±12.0(62)§§++ |
| E | 44.3±4.21(69)+ | 1.11±0.09(69)+ | 12.4±0.56(69)+ | 8.9±4.12(69)+ | 197±85.4(68)+ |
| F | 38.7±5.4(68) | 1.08±0.04(66) | 11.7±0.80(68) | 15.5±8.02(68) | 107±59.0(68) |
* with B group compares P < 0.01* with B group and compares P < 0.05
P < 0.01 is compared with C groupP < 0.05 is compared with C group
++P < 0.01 is compared with E group；+ compare P < 0.05 with E group
§§P < 0.01 is compared with F group；§ with F group compares P < 0.05
Antidepressant is evaluated
Observing the dams caring to cub, dams self is actively and negative behavior, application forced swim test detection
Dams is saved oneself behavioral duration.
Behavioristics is detected
Caring: in puerperal 4th day, children Mus is scattered in mouse cage corner, is placed in mouse cage central authorities, Mus by dams
Hanging video camera directly over cage at 100cm and carry out record, every dams record time is 30min.Love cub behavior: hold in the mouth or the eyes son and dive
Fu Qi: dams has held in the mouth or the eyes the time of the 1st young Mus；The collection nest time: the time that all children Mus are concentrated by dams；Lick the son time: dams
Lick with tongue or head continues the total time of more than 3s at children's Mus head back of the body and anus surrounding genital；Hold in the mouth or the eyes son frequency: dams has been held in the mouth or the eyes
The total degree of children Mus.
The positive act of self: dams stands, the total time of exploration behavior of walking about, climb up and over etc..
The negative behavior of self: when dams is motionless, nondirectional stirs bedding and padding, back, squatting position, pawl, tail do not stop disturbance total
Between.
Forced swim test
In the bucket that about 60cm is high, put into 37 DEG C of warm water of about 30cm height, swim the 5th day puerperal or the 6th day
Experiment, hangs video camera at 100cm above distance bucket and carries out record.Swimming continuance time: rat swashes toward chime and uses fore paw
The temporal summation of significantly horizontal movement is done in water；Non-swimming time: rat is only cooked a small amount of slight oscillatory in water and keeps
The time that head does not sinks.
Statistical method
SPSS16.0 software is used to carry out t inspection.
Result
The comparison of each group dams love cub behavior
A group in depressed group, C dams holds in the mouth or the eyes son incubation period and collection nest time, negative behavior are considerably longer than B group (P ＜ 0.01), female
Mus is held in the mouth or the eyes son frequency and licks the son time, positive act is substantially less than B group (P ＜ 0.01)；A group and C group each index zero difference (P >
0.05)。
D group in non-depressed group, F group dams hold in the mouth or the eyes son incubation period and collection nest time, negative behavior are considerably longer than E group (P ＜
0.05), dams is held in the mouth or the eyes son frequency and licks the son time, positive act is substantially less than E group (P ＜ 0.05)；D group and F group each index indifference
Different (P > 0.05).
Result see table.
| Group | Hold in the mouth or the eyes son incubation period (s) | Collection nest time (%) | Lick the son time (%) | Hold in the mouth or the eyes son frequency (secondary) | Positive act | Negative behavior |
| A | 17.48±1.05** | 12.65±1.59** | 8.09±1.8** | 9.87±2.45** | 9.65±1.54** | 48.14±4.56** |
| B | 13.12±0.49 | 7.16±01.21 | 20.31±2.98 | 14.98±2.87 | 19.48±2.66 | 18.41±3.39 |
| C | 17.41±0.52** | 11.81±1.34** | 8.56±1.89** | 9.28±2.95** | 9.59±3.01** | 48.98±2.19** |
| D | 14.52±1.21+ | 7.96±1.52+ | 17.23±1.5+ | 13.25±1.43+ | 17.29±1.48+ | 18.59±5.29+ |
| E | 12.58±0.78 | 6.55±0.99 | 21.35±3.12 | 15.00±1.08 | 20.54±2.87 | 17.74±2.05 |
| F | 14.55±1.32+ | 7.35±1.25+ | 17.09±2.85+ | 13.56±2.45+ | 17.85±2.95+ | 18.58±3.79+ |
* with B group compares P < 0.01
+ compare P < 0.05 with E group
The dams behavior in forced swim test of each group is compared
A group in depressed group, C group dams are saved oneself persistent period and all substantially less than B group (P ＜ 0.01) motionless incubation period, and
The desperate dead time is considerably longer than B group (P ＜ 0.01).A group and C group index of correlation are without significant difference (P > 0.05).
Non-depressed group of D group, F group compare with E group, D group, F group dams save oneself the persistent period and motionless incubation period the lowest
In E group (P ＜ 0.05), and the desperate dead time is considerably longer than E group (P ＜ 0.05).D group and F group index of correlation are without significant difference
(P>0.05)。
* with B group compares P < 0.01
+ compare P < 0.05 with E group
Brief summary
By result of the test, B group antidepressant index is superior to A group and C group, and this shows that I mends in the nutrition of company's exploitation
Filling agent has the effect alleviating depression, depressed group E group index of correlation to be better than D group and F group, and this shows the nutrition of my company's exploitation
Supplement have alleviates depressed effect, and ordinary nutritional supplement act on without this.
Conclusion
Evaluated by trophic function it can be seen that the supplementary of my company's exploitation can provide maternal weight gain, and effect
Fruit is better than ordinary nutritional supplement.
Can be drawn by antidepressant evaluation, the supplementary of my company's exploitation has alleviates depressed effect.
It addition, the puerpera that names up to a hundred are taken product of the present invention by the present invention investigates, the sickness rate fall of postpartum depression
Low 40-50%.
Detailed description of the invention
The following examples can illustrate in greater detail the exploitativeness of the present invention, but limits the present invention the most in any form.
In embodiment 1, First Trimester nutrient combination composition powders, each nutritive element content is:
Preparation method:
After each vitamin, trace element mixing, cross 100 mesh sieves, the pressed powder containing DHA is crossed 100 mesh sieves, by two kinds
Pack after powder mixing, to obtain final product.
In embodiment 2, mid trimester of pregnancy nutrient combination composition powders, each nutritive element content is:
Preparation method:
After each vitamin, trace element mixing, cross 100 mesh sieves, the pressed powder containing DHA is crossed 100 mesh sieves, by two kinds
Pack after powder mixing, to obtain final product.
In embodiment 3, late trimester of pregnancy nutrient combination composition powders, each nutritive element content is:
Preparation method:
1) by each vitamin, trace element, containing DHA pressed powder mixing after cross 100 mesh sieves；
2) by above-mentioned powder with cross the oligofructose of 100 mesh sieves, soybean dietary fiber, microcrystalline Cellulose, mannitol and rectify
After taste agent mix homogeneously, by the soft ability of HPMC solution system of 5%, crossing 16 mesh sieve wet granulars, 40 DEG C are fully dried；
3) carry out sieving granulate with 10 mesh and 80 mesh sieves by dry granule；
4) pick test, qualified after carry out subpackage, packaging, get product.
In embodiment 4, age of sucking nutrient combination composition powders, the weight proportion of each component is:
Preparation method:
1) by each vitamin, trace element, containing DHA pressed powder mixing after cross 100 mesh sieves；
2) by above-mentioned powder with cross the oligofructose of 100 mesh sieves, soybean dietary fiber, microcrystalline Cellulose, mannitol and rectify
After taste agent mix homogeneously, by the soft ability of HPMC solution system of 5%, crossing 16 mesh sieve wet granulars, 40 DEG C are fully dried；
3) carry out sieving granulate with 10 mesh and 80 mesh sieves by dry granule；
4) pick test, qualified after carry out subpackage, packaging, get product.
In embodiment 5, energy nutrient compositions Emulsion, the weight proportion of each composition is:
Preparation method:
1) preparation of oil phase: Oleum Brassicae campestris, Semen Lini oil and high oleic sunflower oil are added in oil tank, at nitrogen air-flow protection
Under, heat and be stirred to dissolve；
2) preparation of aqueous phase: purified water adds in NaOH solution tank NaOH, adds soybean protein isolate, casein, maltodextrin and rectifys
Taste agent, under nitrogen air-flow protection, heats and stirs；
3) colostrum processed: oil phase and aqueous phase are mixed, uses dispersion machine to carry out emulsifying, prepares colostrum；
4) pH regulator: using sodium hydroxide solution, regulation pH value is to 6.5；
5) constant volume: add water and be settled to full dose；
6) high pressure homogenize: material, through high pressure homogenizer homogenizing 2～4 times under the conditions of pressure is 200bar, at pressure is
Homogenizing 2～4 times under the conditions of 400bar；
7) fill: nitrogen charging fill；
8) sterilizing: 121 DEG C of rotary water bath sterilizings 12 minutes；
9) labeling, pack, put in storage.
Claims (10)
1. the energy nutrient compositions for pregnant and lying-in women, it is characterised in that described compositions is selected from vitamins and minerals group
Part and power pack, wherein said vitamins and minerals assembly contains following component
Wherein said power pack contains following component: protein, fat, carbohydrate, three accounts for power pack weight respectively
The 12%～20%, 20%～30% of amount, 55%～65%.
2. according to the compositions described in claim 1, it is characterised in that wherein said vitamins and minerals assembly contains following one-tenth
Point:
(1) First Trimester:
3. according to the compositions described in claim 1, it is characterised in that wherein said vitamins and minerals assembly contains following one-tenth
Point:
(2) mid trimester of pregnancy:
4. according to the compositions described in claim 1, it is characterised in that wherein said vitamins and minerals assembly contains following one-tenth
Point:
(3) late trimester of pregnancy:
5. according to the compositions described in claim 1, it is characterised in that wherein said vitamins and minerals assembly contains following one-tenth
Point:
(4) age of sucking:
6. according to the compositions described in claim 1, it is characterised in that the protein in wherein said power pack is selected from animal
Protein and phytoprotein, wherein animal protein is selected from: in casein, lactalbumin, collagen protein, Chicken Albumin
Plant or several；Phytoprotein is selected from: soybean protein, Semen Pisi sativi protein, Semen phaseoli radiati albumen, Semen sojae atricolor albumen, wheat protein, Semen Maydis egg
In vain, Semen oryzae sativae albumen, avenin, seed of Fructus Hippophae albumen, spirulina protein, chlorella albumen, scenedesmus albumen one or more,
Fat in wherein said power pack is selected from: Petiolus Trachycarpi oil, Oleum Cocois, Oleum Brassicae campestris (including Canola oil), Caulis et Folium Lini
Seed oil, sunflower oil (including high oleic sunflower oil), soybean oil, safflower oil (including high oleic safflower oil), Radix Oenotherae erythrosepalae oil, seed of Fructus Hippophae
One or more in oil, Oleum Hippophae, olive oil, walnut oil, fish oil,
Carbohydrate in wherein said power pack is selected from: fructose, glucose, sucrose, maltose, isomaltulose, wood
One or more in sugar alcohol, maltodextrin, tapioca, corn starch, potato starch, sweet potato starch, modified starch.
7. according to the compositions described in claim 1, it is characterised in that described compositions is prepared to the preparation being suitable for taking
Form, described preparation is selected from: powder, granule, capsule, tablet, Emulsion.
8., according to the compositions described in claim 7, it is characterised in that described dosage form, wherein comprise the load that can take
Body, described carrier is selected from filler, binding agent, lubricant, correctives, surfactant, and wherein filler forms sediment selected from compressibility
One or more in powder, pregelatinized Starch, mannitol, microcrystalline Cellulose, lactose, binding agent is selected from polyvidone, hydroxypropyl
Cellulose, Carboxymethyl cellulose sodium, hydroxypropyl cellulose, ethyl cellulose one or more, lubricant selected from magnesium stearate,
Sodium stearyl fumarate, micropowder silica gel and talcous one or more, surfactant be selected from soybean phospholipid and derivant, ovum
One or more in phospholipid and derivant, tween, span.
9. the preparation method of the compositions described in claim 1, it is characterised in that include the step of each composition mixing in prescription
Suddenly.
10. according to the preparation method described in claim 9, it is characterised in that wherein vitamins and minerals assembly and power pack
Being prepared as preparation respectively, wherein vitamins and minerals assembly is prepared as solid preparation, and concrete preparation process comprises the following steps:
1), after vitamin, trace element mixing, 100 mesh sieves are crossed；
2), the solid containing DHA is crossed 100 mesh sieves；
3), by packing after above two powder mix homogeneously, powder is i.e. obtained；
4) or by after above two powder mix homogeneously, add appropriate amount of auxiliary materials and make granule, make corresponding preparation the most again；
Wherein power pack is prepared as Emulsion, and the concrete preparation process of Emulsion comprises the following steps:
1) oil phase and aqueous phase, are prepared；
2), oil phase and aqueous phase are mixed, use high speed emulsion dispersion machine to carry out emulsifying, prepare colostrum；
3), regulate to target ph with sodium hydroxide solution, add water and be settled to full dose；
4) use high pressure homogenizer homogenizing, again, obtain homogeneous latex emulsion；
5), fill, sterilizing, to obtain final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610350096.3A CN105942510A (en) | 2016-05-24 | 2016-05-24 | Medical energy nutrition component applied to pregnant and lying-in women and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610350096.3A CN105942510A (en) | 2016-05-24 | 2016-05-24 | Medical energy nutrition component applied to pregnant and lying-in women and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105942510A true CN105942510A (en) | 2016-09-21 |
Family
ID=56909580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610350096.3A Pending CN105942510A (en) | 2016-05-24 | 2016-05-24 | Medical energy nutrition component applied to pregnant and lying-in women and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105942510A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108208808A (en) * | 2018-01-19 | 2018-06-29 | 云南省第三人民医院 | A kind of pregnant woman's postpartum alimentation composition |
| CN108741061A (en) * | 2018-04-10 | 2018-11-06 | 陕西三正医用营养有限公司 | A kind of special diet food and preparation method thereof applied to pregnancy period conditioning |
| CN109380722A (en) * | 2018-10-23 | 2019-02-26 | 珠海横琴普罗恩能医用食品有限公司 | A kind of puerpera's stages of labor energy extender |
| CN110101088A (en) * | 2019-05-09 | 2019-08-09 | 武汉正轩宇生物科技有限公司 | Accurate nutritional meal replacement composition and its application method for gestational diabetes mellitus prevention and treatment |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020102330A1 (en) * | 2000-12-05 | 2002-08-01 | Pbm Products, Inc. | Food bars containing nutritional supplements and anti-constipation and regularity -maintaining agents |
| CN1463745A (en) * | 2002-06-14 | 2003-12-31 | 丁强 | Replenisher containing complete nutrescin |
| CN1672541A (en) * | 2005-04-21 | 2005-09-28 | 石家庄三鹿集团股份有限公司 | Pregnant woman benefiting milk powder |
| CN1846776A (en) * | 2005-04-12 | 2006-10-18 | 天津天士力制药股份有限公司 | Injection of long-chain fat from zedoary oil and its prepn process |
| CN101313717A (en) * | 2008-07-09 | 2008-12-03 | 内蒙古蒙牛乳业（集团）股份有限公司 | Liquid milk with additive vitamin suitable for pregnant woman drink and preparation method thereof |
| CN101313713A (en) * | 2008-07-09 | 2008-12-03 | 内蒙古蒙牛乳业（集团）股份有限公司 | Liquid state milk suitable for pregnant woman drink and preparation thereof |
| CN101433240A (en) * | 2007-11-16 | 2009-05-20 | 光明乳业股份有限公司 | Edible milk suitable for pregnant woman and nursing mother and preparation method thereof |
| CN105410943A (en) * | 2015-11-30 | 2016-03-23 | 广州市富诺生物科技有限公司 | Compound vitamin tablets and preparation method thereof |
-
2016
- 2016-05-24 CN CN201610350096.3A patent/CN105942510A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020102330A1 (en) * | 2000-12-05 | 2002-08-01 | Pbm Products, Inc. | Food bars containing nutritional supplements and anti-constipation and regularity -maintaining agents |
| CN1463745A (en) * | 2002-06-14 | 2003-12-31 | 丁强 | Replenisher containing complete nutrescin |
| CN1846776A (en) * | 2005-04-12 | 2006-10-18 | 天津天士力制药股份有限公司 | Injection of long-chain fat from zedoary oil and its prepn process |
| CN1672541A (en) * | 2005-04-21 | 2005-09-28 | 石家庄三鹿集团股份有限公司 | Pregnant woman benefiting milk powder |
| CN101433240A (en) * | 2007-11-16 | 2009-05-20 | 光明乳业股份有限公司 | Edible milk suitable for pregnant woman and nursing mother and preparation method thereof |
| CN101313717A (en) * | 2008-07-09 | 2008-12-03 | 内蒙古蒙牛乳业（集团）股份有限公司 | Liquid milk with additive vitamin suitable for pregnant woman drink and preparation method thereof |
| CN101313713A (en) * | 2008-07-09 | 2008-12-03 | 内蒙古蒙牛乳业（集团）股份有限公司 | Liquid state milk suitable for pregnant woman drink and preparation thereof |
| CN105410943A (en) * | 2015-11-30 | 2016-03-23 | 广州市富诺生物科技有限公司 | Compound vitamin tablets and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 王楠: "《怀孕280天专家指导》", 31 January 2015, 中国纺织出版社 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108208808A (en) * | 2018-01-19 | 2018-06-29 | 云南省第三人民医院 | A kind of pregnant woman's postpartum alimentation composition |
| CN108741061A (en) * | 2018-04-10 | 2018-11-06 | 陕西三正医用营养有限公司 | A kind of special diet food and preparation method thereof applied to pregnancy period conditioning |
| CN109380722A (en) * | 2018-10-23 | 2019-02-26 | 珠海横琴普罗恩能医用食品有限公司 | A kind of puerpera's stages of labor energy extender |
| CN110101088A (en) * | 2019-05-09 | 2019-08-09 | 武汉正轩宇生物科技有限公司 | Accurate nutritional meal replacement composition and its application method for gestational diabetes mellitus prevention and treatment |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101278705B (en) | Feed stuff for sow in later stage of pregnancy and lactation period | |
| CN106983136A (en) | A kind of puerperium conditioning tailored version clinical nutrition formula and preparation method thereof | |
| CN107242550A (en) | A kind of male sterility tailored version clinical nutrition formula and preparation method thereof | |
| CN106490605A (en) | A kind of hypertension of pregnancy tailored version clinical nutrition formula and preparation method thereof | |
| CN1868302B (en) | Chinese herb medicine additive for chicken feed | |
| CN108634324A (en) | A kind of special diet food and preparation method thereof promoting cesarean lactation and nutritional supplementation | |
| US20080003302A1 (en) | Method And Nutraceutical Composition For Mammals | |
| CN106942748A (en) | A kind of female acyesis tailored version clinical nutrition formula and preparation method thereof | |
| CN107927754A (en) | Tailored version clinical nutrition formula and preparation method thereof is energized during one kind production | |
| CN106071224A (en) | A kind of Chinese herbal feed additive for improving sow lactogenic reproductive performance and preparation method thereof | |
| CN105942510A (en) | Medical energy nutrition component applied to pregnant and lying-in women and preparation method thereof | |
| CN101869224A (en) | Feed additive for improving lactation performance of lactating sows and preparation method thereof | |
| CN109414053A (en) | It is supported via the Animal nutrition for giving the supplement from algae | |
| CN107348483A (en) | A kind of pregnant and lying-in women's full function nutritious supplementary pharmaceutical | |
| CN110301629A (en) | A kind of full nutrient solid beverage of tumor patient and preparation method thereof | |
| CN105707707A (en) | Super quinoa nutrition powder for pregnant and lying-in women | |
| CN108741061A (en) | A kind of special diet food and preparation method thereof applied to pregnancy period conditioning | |
| CN104905027A (en) | Quail feed capable of enhancing immunity | |
| CN101904507A (en) | Ferrous bisglycinate chelate nutritional composition and application thereof | |
| CN108013452A (en) | A kind of puerperal abdominal flatulence gas tailored version clinical nutrition formula and preparation method thereof | |
| CN103598405A (en) | Feed for improving egg quality of layer chickens | |
| CN109123660A (en) | A kind of walnut lactalbumin composite powder and preparation method thereof for maternal nutritional product | |
| CN105146228A (en) | Chinese herb compound preparation used for sow miscarriage prevention and preparing method thereof | |
| CN101869225B (en) | Feed additive for improving pregnancy rate of sows and preparation method thereof | |
| CN106668119A (en) | Milking sow premix feed capable of improving milking capacity and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 100176 Beijing Beijing economic and Technological Development Zone, Chuang Chuang thirteen Street 31 hospital two District 7 Building 101 room. Applicant after: Beijing nukangda medicine Polytron Technologies Inc Address before: 100176 Beijing Fengtai District Beijing economic and Technological Development Zone Yongchang road 3 No. 8 Yongchang science and Technology Plaza 505 room Applicant before: BEIJING NUOKANGDA PHARMACEUTICAL CO., LTD. |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160921 |